Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?

Detalhes bibliográficos
Autor(a) principal: Boal Carvalho, Pedro
Data de Publicação: 2017
Outros Autores: Magalhães, Joana, Dias de Castro, Francisca, Rosa, Bruno, Cotter, José
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072
Resumo: Introduction: Helicobacter pylori eradication has become increasingly difficult as resistances to several antibiotics develop. We aimed to compare Helicobacter pylori eradication rates between triple therapy and sequential therapy in a naive Portuguese population.Material and Methods: Prospective randomized trial including consecutive patients referred for first-line Helicobacter pylori eradication treatment. Exclusion criteria: previous gastric surgery/neoplasia, pregnancy/lactancy, allergy to any of the drugs. The compared eradication regimens were triple therapy (pantoprazol, amoxicillin and clarithromycin 12/12 hours, 14 days) and sequential therapy (pantoprazol 12/12 hours for 10 days, amoxicillin 12/12 hours for days 1 - 5 and clarithromycin plus metronidazol 12/12 hours during days 6 - 10). Eradication success was confirmed with urea breath test. Statistical analysis was performed with SPSS v21.0 and a p-value < 0.05 was considered statistically significant.Results: Included 60 patients, 39 (65%) female with mean age 52 years (SD ± 14.3). Treatment groups were homogeneous for gender, age, indication for treatment and smoking status. No statistical differences were encountered between sequential and triple therapy eradication rates (86.2% vs 77.4%, p = 0.379), global eradication rate was 82%. Tobacco consumption was associated with a significantly lower eradication success (54.5 vs 87.8%, p = 0.022).Discussion: In this randomized controlled trial in a naive Portuguese population, we found a satisfactory global Helicobacter pylori eradication rate of 82%, with no statistical differences observed in the efficacy of the treatment between triple and sequential regimens.Conclusion: These results support the use of either therapy for the first-line eradication of Helicobacter pylori.
id RCAP_21a3e5e875413d520b4af6b81ee0a2c1
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/8072
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?Ensaio Clínico Randomizado para o Tratamento do Helicobacter pylori em Doentes Portugueses Naive: É o Tratamento Sequencial Superior ao Tratamento Triplo na Prática Clínica?Anti-Bacterial AgentsDrug TherapyCombinationHelicobacter Infections/drug therapyHelicobacter pyloriPortugalStomach NeoplasmsFarmacoterapia CombinadaHelicobacter pyloriInfecções por Helicobacter/tratamentoNeoplasias do EstômagoPortugalIntroduction: Helicobacter pylori eradication has become increasingly difficult as resistances to several antibiotics develop. We aimed to compare Helicobacter pylori eradication rates between triple therapy and sequential therapy in a naive Portuguese population.Material and Methods: Prospective randomized trial including consecutive patients referred for first-line Helicobacter pylori eradication treatment. Exclusion criteria: previous gastric surgery/neoplasia, pregnancy/lactancy, allergy to any of the drugs. The compared eradication regimens were triple therapy (pantoprazol, amoxicillin and clarithromycin 12/12 hours, 14 days) and sequential therapy (pantoprazol 12/12 hours for 10 days, amoxicillin 12/12 hours for days 1 - 5 and clarithromycin plus metronidazol 12/12 hours during days 6 - 10). Eradication success was confirmed with urea breath test. Statistical analysis was performed with SPSS v21.0 and a p-value < 0.05 was considered statistically significant.Results: Included 60 patients, 39 (65%) female with mean age 52 years (SD ± 14.3). Treatment groups were homogeneous for gender, age, indication for treatment and smoking status. No statistical differences were encountered between sequential and triple therapy eradication rates (86.2% vs 77.4%, p = 0.379), global eradication rate was 82%. Tobacco consumption was associated with a significantly lower eradication success (54.5 vs 87.8%, p = 0.022).Discussion: In this randomized controlled trial in a naive Portuguese population, we found a satisfactory global Helicobacter pylori eradication rate of 82%, with no statistical differences observed in the efficacy of the treatment between triple and sequential regimens.Conclusion: These results support the use of either therapy for the first-line eradication of Helicobacter pylori.Introdução: A erradicação do Helicobacter pylori tem adquirido dificuldade progressiva, devido às resistências para os antibióticos utilizados. Pretendemos comparar a eficácia na erradicação do Helicobacter pylori entre o tratamento triplo e sequencial numa população portuguesa naive.Material e Métodos: Trabalho prospectivo randomizado incluindo doentes consecutivos submetidos a primeiro tratamento de erradicação do Helicobacter pylori. Critérios de exclusão: cirurgia/neoplasia gástrica prévias, gravidez/aleitamento, alergia a algum dos fármacos. Os esquemas utilizados foram o tratamento triplo (pantoprazol, amoxicilina claritromicina 12/12 horas, 14 dias) e tratamento sequencial (pantoprazol 12/12 horas durante 10 dias, amoxicilina 12/12 horas nos dias 1 - 5 e claritromicina e metronidazol 12/12 horas nos dias 6 - 10). A eficácia da erradicação foi confirmada com um teste respiratório da ureia. A análise estatística foi efectuada com o SPSS v21.0 e um valor de p < 0,05 foi considerado estatisticamente significativo.Resultados: Incluídos 60 doentes, 39 (65%) mulheres, idade média 52 anos (DP ± 14,3). Os grupos de tratamento foram homogéneos para as variáveis sexo, idade, indicação para tratamento e tabagismo. Não foram observadas diferenças estatisticamente significativas na eficácia de erradicação do Helicobacter pylori entre o tratamento triplo e sequencial (86,2% vs 77,4%, p = 0,379), com uma taxa global de erradicação de 82%. O tabagismo foi associado significativamente a uma menor eficácia de erradicação (54,5 vs 87,8%, p = 0,022).Discussão: Neste ensaio clínico randomizado numa população portuguesa naive, encontrámos uma eficácia global de erradicacão do Helicobacter pylori de 82%, sem diferenças estatisticamente significativas entre o tratamento triplo e o tratamento sequencial.Conclusão: Estes resultados reforçam a possibilidade de utilizar qualquer um destes tratamentos como primeira linha na erradicação do Helicobacter pylori.Ordem dos Médicos2017-03-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/mswordapplication/pdfapplication/mswordhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072oai:ojs.www.actamedicaportuguesa.com:article/8072Acta Médica Portuguesa; Vol. 30 No. 3 (2017): March; 185-189Acta Médica Portuguesa; Vol. 30 N.º 3 (2017): Março; 185-1891646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072/4967https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072/8636https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072/8696https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072/8840Direitos de Autor (c) 2017 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessBoal Carvalho, PedroMagalhães, JoanaDias de Castro, FranciscaRosa, BrunoCotter, José2022-12-20T11:05:25Zoai:ojs.www.actamedicaportuguesa.com:article/8072Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:32.637009Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
Ensaio Clínico Randomizado para o Tratamento do Helicobacter pylori em Doentes Portugueses Naive: É o Tratamento Sequencial Superior ao Tratamento Triplo na Prática Clínica?
title Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
spellingShingle Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
Boal Carvalho, Pedro
Anti-Bacterial Agents
Drug Therapy
Combination
Helicobacter Infections/drug therapy
Helicobacter pylori
Portugal
Stomach Neoplasms
Farmacoterapia Combinada
Helicobacter pylori
Infecções por Helicobacter/tratamento
Neoplasias do Estômago
Portugal
title_short Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
title_full Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
title_fullStr Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
title_full_unstemmed Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
title_sort Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
author Boal Carvalho, Pedro
author_facet Boal Carvalho, Pedro
Magalhães, Joana
Dias de Castro, Francisca
Rosa, Bruno
Cotter, José
author_role author
author2 Magalhães, Joana
Dias de Castro, Francisca
Rosa, Bruno
Cotter, José
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Boal Carvalho, Pedro
Magalhães, Joana
Dias de Castro, Francisca
Rosa, Bruno
Cotter, José
dc.subject.por.fl_str_mv Anti-Bacterial Agents
Drug Therapy
Combination
Helicobacter Infections/drug therapy
Helicobacter pylori
Portugal
Stomach Neoplasms
Farmacoterapia Combinada
Helicobacter pylori
Infecções por Helicobacter/tratamento
Neoplasias do Estômago
Portugal
topic Anti-Bacterial Agents
Drug Therapy
Combination
Helicobacter Infections/drug therapy
Helicobacter pylori
Portugal
Stomach Neoplasms
Farmacoterapia Combinada
Helicobacter pylori
Infecções por Helicobacter/tratamento
Neoplasias do Estômago
Portugal
description Introduction: Helicobacter pylori eradication has become increasingly difficult as resistances to several antibiotics develop. We aimed to compare Helicobacter pylori eradication rates between triple therapy and sequential therapy in a naive Portuguese population.Material and Methods: Prospective randomized trial including consecutive patients referred for first-line Helicobacter pylori eradication treatment. Exclusion criteria: previous gastric surgery/neoplasia, pregnancy/lactancy, allergy to any of the drugs. The compared eradication regimens were triple therapy (pantoprazol, amoxicillin and clarithromycin 12/12 hours, 14 days) and sequential therapy (pantoprazol 12/12 hours for 10 days, amoxicillin 12/12 hours for days 1 - 5 and clarithromycin plus metronidazol 12/12 hours during days 6 - 10). Eradication success was confirmed with urea breath test. Statistical analysis was performed with SPSS v21.0 and a p-value < 0.05 was considered statistically significant.Results: Included 60 patients, 39 (65%) female with mean age 52 years (SD ± 14.3). Treatment groups were homogeneous for gender, age, indication for treatment and smoking status. No statistical differences were encountered between sequential and triple therapy eradication rates (86.2% vs 77.4%, p = 0.379), global eradication rate was 82%. Tobacco consumption was associated with a significantly lower eradication success (54.5 vs 87.8%, p = 0.022).Discussion: In this randomized controlled trial in a naive Portuguese population, we found a satisfactory global Helicobacter pylori eradication rate of 82%, with no statistical differences observed in the efficacy of the treatment between triple and sequential regimens.Conclusion: These results support the use of either therapy for the first-line eradication of Helicobacter pylori.
publishDate 2017
dc.date.none.fl_str_mv 2017-03-31
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072
oai:ojs.www.actamedicaportuguesa.com:article/8072
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/8072
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072/4967
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072/8636
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072/8696
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8072/8840
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2017 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2017 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/msword
application/pdf
application/msword
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 30 No. 3 (2017): March; 185-189
Acta Médica Portuguesa; Vol. 30 N.º 3 (2017): Março; 185-189
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130645917597696